Read the full article on The Market Herald here.
- From burn wound studies to COVID-combatting drugs, Recce Pharmaceuticals (RCE) made impressive progress over 2020's final quarter
- The company received formal approval to commence clinical trials of its R327 antibiotic on patients with infected burn wounds
- Recce also wrapped up studies confirming the effectiveness of it anti-infective drugs in combatting COVID-19 In terms of finances, the company is sitting with roughly $23.6 million in cash and equivalents
Recce Pharmaceuticals (ASX:RCE) reveals highlights from December 2020 quarter
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.035(9.33%) |
Mkt cap ! $118.5M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 41.5¢ | 38.0¢ | $77.51K | 190.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1250 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 15479 | 1 |
View Market Depth
| Last trade - 16.10pm 11/08/2025 (20 minute delay) ? |
| RCE (ASX) Chart |